Yes, Bystolic (nebivolol) is a beta-blocker. It belongs to a newer generation of beta-blockers that works differently from older options like metoprolol or atenolol. The FDA approved it specifically for treating high blood pressure, and it can be used alone or alongside other blood pressure medications.
What makes Bystolic stand out in the beta-blocker class is a combination of unusually high selectivity for the heart and an additional ability to relax blood vessels, a trait most beta-blockers lack. These properties translate into real differences in side effects and metabolic impact.
How Bystolic Differs From Other Beta-Blockers
All beta-blockers lower blood pressure by slowing the heart rate and reducing the force of each heartbeat. They do this by blocking beta receptors, which come in two main types. Beta-1 receptors sit primarily on heart cells, while beta-2 receptors are found in the lungs, blood vessels, and other tissues. Older, non-selective beta-blockers hit both types, which is why they can cause side effects like airway tightening and cold hands.
Bystolic is highly selective for beta-1 receptors at standard doses (10 mg or less). In binding studies on human heart tissue, nebivolol was roughly 3.5 times more selective for beta-1 receptors than bisoprolol, which is itself considered a selective beta-blocker. At higher doses or in people who metabolize the drug slowly (a small percentage of the population), it begins blocking beta-2 receptors as well.
The other distinguishing feature is that Bystolic triggers the release of nitric oxide, a molecule that relaxes and widens blood vessels. It does this by activating a third type of receptor (beta-3), which most other beta-blockers don’t meaningfully interact with. The result is lower resistance in blood vessels throughout the body, which helps maintain healthy blood flow even as the heart rate drops. Research published in the American Heart Association’s journal Hypertension confirmed that this nitric oxide pathway reduces peripheral resistance and helps preserve cardiac output during treatment.
What Bystolic Is Prescribed For
The sole FDA-approved indication for Bystolic is hypertension. It has not been approved for heart failure, chest pain, or heart rhythm disorders, though some beta-blockers carry those indications. The FDA label notes that while lowering blood pressure generally reduces the risk of strokes and heart attacks, no controlled trials have demonstrated that specific benefit with Bystolic itself.
The typical starting dose is 5 mg once daily, and your doctor may adjust it based on your response. Generic nebivolol has been available in the U.S. since 2015 in 2.5 mg, 5 mg, 10 mg, and 20 mg tablets, making it more affordable than the brand-name version.
Metabolic Advantages Over Older Beta-Blockers
One long-standing concern with beta-blockers is their tendency to worsen insulin sensitivity and blood sugar control, a problem for people with or at risk for diabetes. A randomized, double-blind study compared 12 weeks of Bystolic against metoprolol in patients with metabolic syndrome. Both drugs lowered blood pressure and heart rate equally, but metoprolol significantly decreased insulin sensitivity while Bystolic did not. The difference between the two was statistically meaningful.
The same study found that metoprolol raised levels of a protein (PAI-1) linked to blood clot risk and increased markers of oxidative stress. Bystolic did neither. The researchers concluded that nebivolol has a “favorable effect on fibrinolytic balance” and lacks the negative metabolic effects seen with metoprolol. For people who already have risk factors for diabetes or cardiovascular disease, this distinction can matter.
Side Effects
The most commonly reported side effects of Bystolic include headache, fatigue, dizziness, nausea, diarrhea, and difficulty sleeping. Some people also notice numbness or tingling in the hands and feet. These are consistent with the beta-blocker class in general, though the severity tends to be milder for many patients because of the drug’s selectivity.
Sexual dysfunction is a well-known complaint with beta-blockers, and Bystolic performs notably better on this front. A prospective crossover trial found that metoprolol caused significant declines in erectile function scores across multiple patient groups, while Bystolic did not. Even in men who had no erectile issues before treatment, metoprolol caused a larger drop in sexual function than Bystolic did. This difference is likely related to the nitric oxide release that improves blood vessel relaxation.
Who Should Not Take Bystolic
Bystolic is contraindicated in several situations: a very slow heart rate, heart block beyond first degree (unless you have a pacemaker), cardiogenic shock, decompensated heart failure, sick sinus syndrome without a pacemaker, and severe liver impairment. These restrictions are common across most beta-blockers, since the drug class works by slowing heart activity and could be dangerous when the heart’s electrical system or pumping ability is already compromised.
As with all beta-blockers, you should not stop taking Bystolic abruptly. Sudden discontinuation can cause a rebound spike in heart rate and blood pressure, which may be dangerous for people with underlying heart conditions. If your doctor decides to stop the medication, the dose is typically tapered over one to two weeks.